Poster

Historical Control Database Of Cynomolgus Macaque Spermatozoa

Source: Altasciences

By A. Celori, L. Baydak, , S. McGrath, S. Kaur, J. Hynek, and J. Forget

GettyImages-2165707549_sperm bank

The evaluation of sperm quality is crucial for assessing the potential adverse effects of pharmaceuticals on male reproductive health, with standard assessments focusing on motility, concentration, and morphology. While the cynomolgus macaque is frequently used in studies, particularly for biotechnology-derived drugs, ICH S5(R2) highlights a lack of historical data on non-human primates (NHPs) in this area. Currently, NHP semen evaluation largely relies on the WHO Laboratory Manual for Human Semen Examination and Processing, but there are few studies detailing normal cynomolgus macaque sperm, limiting the translatability of findings. Establishing robust criteria for normal NHP sperm is essential for accurately interpreting potential toxicological effects.

To address this gap, data from over 400 NHPs between 2007 and 2019 were collected, including sperm concentration, motility, and morphology, to create a historical control database. All animals were either naïve or administered a control/sham article. Sperm was collected via penile electrostimulation, and ejaculate volume, motility, and concentration were assessed using the TOX IVOS or TOX IVOS II CASA systems, while morphology was examined using light microscopy. Descriptive statistics (mean, SD, and quartile ranges) were generated to establish normal sperm parameters for future interpretation of cynomolgus macaque sperm.

access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Discovery Online